MedPath

ILIKANNU'S TRIA

Not Applicable
Conditions
Pregnancy and Childbirth
Registration Number
PACTR202206623958155
Lead Sponsor
DR ILIKANNU SAMUEL OKWUCHUKW
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
146
Inclusion Criteria

1.Willingness and consent to participate in the study
2.All patients above 20weeks of gestation with severe preeclampsia
3.Patients without contraindication to the use of MgSO4 (e.g drug hypersensitivity, myasthenia gravis, anuria/oliguria).

Exclusion Criteria

1.Eclampsia
2.Seizure disorder patients
3.Severe preeclampsia with complications like Acute renal failure, Heart failure, HELLP syndrome, pulmonary oedema
4.Prior intake of any anticonvulsant before presentation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
OCCURENCE OF SEIZURES IN BOTH ARM
Secondary Outcome Measures
NameTimeMethod
TOTAL DOSE OF MGSO4 ADMINISTERED, DURATION OF URETHRAL CATHETERIZATION IN DAYS, DURATION OF HOSPITAL STAY IN DAYS, OCCURENCE OF MATERNAL MORTALITY, ADVERSE EFFECTS AND EVIDENCE OF TOXICITY CLINICALLY, MODE OF DELIVERY, ADMISSION INTO ICU, NEED TO RECOMMENCE MGSO4
© Copyright 2025. All Rights Reserved by MedPath